Theranostic nanoparticles engineered for clinic and pharmaceutics.

Nanomedicine is the manipulation of human biological systems at the molecular level using nanoscale or nanostructured materials. Because nanoscale materials interact effectively with biological systems, the use of nanodiagnostics and nanotherapeutics may overcome many intractable health challenges. A variety of nanoparticles have been designed with modifiable functional surfaces and bioactive cores. The engineering of nanoparticles can result in several advantageous therapeutic and diagnostic properties including enhanced permeation and retention in the circulatory system, specific delivery of drugs to target sites, highly-efficient gene transfection, and enhanced medical imaging. These nanoscale materials offer the opportunity to detect chronic diseases early and to monitor the therapeutic effects of nanoformulated drugs used in the clinic. Many of these novel nanoparticles contain both drug(s) and imaging agent(s) within an individual nanoparticle for simultaneous disease diagnosis and therapy. Further integration of therapeutic compounds with diagnostic agents into theranostic nanoparticles would be highly beneficial. However, the unique physiochemical properties that make nanomaterials attractive for therapy and diagnosis may be also associated with potential health hazards. Our research has demonstrated that the biological response to nanomaterials is related to many factors including exposure levels, systemic accumulation and excretion profiles, tissue and organ distribution, and the age of the test subject. Therefore, when engineering new nanomaterials for clinical use, researchers need to consider these factors to minimize toxicity of nanoparticles in these applications. We have fabricated and evaluated nanomaterials such as cationic amphiphilic polymers and metallofullerenes that demonstrate both high efficiency and low toxicity in gene therapy and/or chemotherapy. In this Account, we describe the development of theranostic nanomaterials with low toxicity and illustrate their potential use as novel nanomedicines in translational research.

[1]  Y. Lo,et al.  Characterization of pilocarpine‐loaded chitosan/Carbopol nanoparticles , 2006, The Journal of pharmacy and pharmacology.

[2]  Mark E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[3]  M. Kano,et al.  Enhanced in vivo Magnetic Resonance Imaging of Tumors by PEGylated Iron-Oxide-Gold Core-Shell Nanoparticles with Prolonged Blood Circulation Properties. , 2010, Macromolecular rapid communications.

[4]  P. Ortega,et al.  Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Gordana Bogdanović,et al.  Fullerenol C60(OH)24 effects on antioxidative enzymes activity in irradiated human erythroleukemia cell line. , 2008, Journal of Radiation Research.

[6]  A. Vessières,et al.  Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Xing-jie Liang,et al.  Ternary complexes of amphiphilic polycaprolactone-graft-poly (N,N-dimethylaminoethyl methacrylate), DNA and polyglutamic acid-graft-poly(ethylene glycol) for gene delivery. , 2011, Biomaterials.

[8]  Xing-Jie Liang,et al.  Inhibition of Tumor Growth by Endohedral Metallofullerenol Nanoparticles Optimized as Reactive Oxygen Species Scavenger , 2008, Molecular Pharmacology.

[9]  Yan Song,et al.  Potent angiogenesis inhibition by the particulate form of fullerene derivatives. , 2010, ACS nano.

[10]  Benjamin R. Jarrett,et al.  Gold-coated iron nanoparticles: a novel magnetic resonance agent for T1 and T2 weighted imaging , 2006 .

[11]  Michael M. Gottesman,et al.  Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis , 2010, Proceedings of the National Academy of Sciences.

[12]  K. Johnston,et al.  Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. , 2008, Journal of pharmaceutical sciences.

[13]  E. Bilensoy,et al.  Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. , 2008, International journal of pharmaceutics.

[14]  C. Epstein,et al.  A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. , 2004, Free radical biology & medicine.

[15]  Meredith A Mintzer,et al.  Nonviral vectors for gene delivery. , 2009, Chemical reviews.

[16]  J. Benoit,et al.  Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. , 2008, Biomaterials.

[17]  Yaping Li,et al.  The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. , 2009, Biomaterials.

[18]  V. Labhasetwar,et al.  Nanoparticle‐mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia‐reperfusion injury , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  R. Weisman,et al.  Fullerene (C60) Immunoconjugates: Interaction of Water‐Soluble C60 Derivatives with the Murine anti‐gp240 Melanoma Antibody. , 2006 .

[20]  P. Vavia,et al.  Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[21]  Feng Zhao,et al.  Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. , 2005, Nano letters.

[22]  G. Sharma,et al.  Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats , 2009, Pharmaceutical Research.

[23]  M. Ogris,et al.  Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. , 2009, Molecular pharmaceutics.

[24]  G. Robertson,et al.  Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. , 2008, Cancer research.

[25]  V. Rotello,et al.  Protein-passivated Fe(3)O(4) nanoparticles: low toxicity and rapid heating for thermal therapy. , 2008, Journal of materials chemistry.

[26]  Robert Langer,et al.  A Combinatorial Polymer Library Approach Yields Insight into Nonviral Gene Delivery , 2008 .

[27]  Paul C. Wang,et al.  Amphiphilic and biodegradable methoxy polyethylene glycol-block-(polycaprolactone-graft-poly(2-(dimethylamino)ethyl methacrylate)) as an effective gene carrier. , 2011, Biomaterials.

[28]  B. Padhi,et al.  Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary pharmacokinetics , 2007, International journal of nanomedicine.

[29]  S. Betigeri,et al.  Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. , 2008, Bioconjugate chemistry.

[30]  Z. Chai,et al.  The strong MRI relaxivity of paramagnetic nanoparticles. , 2008, Journal of Physical Chemistry B.

[31]  Cheng Luo,et al.  Polyhydroxylated fullerene derivative C60(OH)24 prevents mitochondrial dysfunction and oxidative damage in an MPP+‐induced cellular model of Parkinson's disease , 2008, Journal of neuroscience research.

[32]  Xing-jie Liang,et al.  Poly(ε-caprolactone)-graft-poly(2-(N,N-dimethylamino) ethyl methacrylate) nanoparticles: pH dependent thermo-sensitive multifunctional carriers for gene and drug delivery , 2010 .

[33]  Mu-Yi Hua,et al.  Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain , 2010, Proceedings of the National Academy of Sciences.

[34]  Lihong V. Wang,et al.  Gold nanocages for cancer imaging and therapy. , 2010, Methods in molecular biology.

[35]  Leaf Huang,et al.  An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[36]  X. Qu,et al.  Programmable delivery of hydrophilic drug using dually responsive hydrogel cages. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[37]  T. Park,et al.  Thermally sensitive cationic polymer nanocapsules for specific cytosolic delivery and efficient gene silencing of siRNA: swelling induced physical disruption of endosome by cold shock. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Yang Huang,et al.  The use of PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses. , 2010, Biomaterials.

[39]  N. Zhang,et al.  Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. , 2008, International journal of pharmaceutics.

[40]  J. Xie,et al.  Iron oxide nanoparticle platform for biomedical applications. , 2009, Current medicinal chemistry.

[41]  T. Park,et al.  Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. , 2010, Biomaterials.

[42]  Jia Guo,et al.  Preparation and characterization of chitosan–poly(acrylic acid) polymer magnetic microspheres , 2006 .

[43]  Hua Guo,et al.  [Gd@C(82)(OH)(22)](n) nanoparticles induce dendritic cell maturation and activate Th1 immune responses. , 2010, ACS nano.

[44]  Brian Samuels,et al.  Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.